Recent approvals in gastrointestinal and genitourinary cancers are expanding treatment options with more precise and effective therapies. Pembrolizumab (Keytruda), a PD-1 checkpoint inhibitor, is now approved for colorectal, gastric, and esophageal cancers, showing durable responses, improved survival, and better quality of life for biomarker-selected patients.
Trastuzumab (Herceptin), targeting HER2, benefits patients with HER2-positive gastric and gastroesophageal junction cancers. Combined with chemotherapy, it improves survival and response rates while maintaining a well-established safety profile. Cabozantinib (Cabometyx), a multi-targeted tyrosine kinase inhibitor, addresses tumor heterogeneity in advanced hepatocellular carcinoma by blocking VEGFR, MET, and AXL pathways, providing disease control in refractory cases.
177Lu-PSMA-617 (Pluvicto) is a precision radiopharmaceutical delivering targeted radiation to PSMA-positive metastatic castration-resistant prostate cancer while sparing healthy tissue. Together, these therapies—from immunotherapy and targeted antibodies to multi-pathway inhibitors and radiopharmaceuticals—represent a shift toward personalized, biomarker-driven cancer care, offering improved outcomes and new hope for patients with GI and GU malignancies.